Drug
Fulvestrant
Fulvestrant: highest development phase Phase 2, developed by Atossa Therapeutics, Merck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Atossa Therapeutics, Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fulvestrant NCT02540330 | Phase 2 | Female Breast Carcinoma |
| Fulvestrant NCT00903006 | Phase 1/2 | Breast Cancer |
Latest
No recent events.
Follow Fulvestrant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.